Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02287428
Title Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With MGMT Unmethylated, Newly Diagnosed GBM
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

glioblastoma

giant cell glioblastoma

gliosarcoma

Therapies

NeoVax

Pembrolizumab

Temozolomide

NeoVax + Pembrolizumab + Temozolomide

NeoVax + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Massachusetts General Hospital Not yet recruiting Boston Massachusetts 02113 United States Details
Dana Farber Cancer Institute Recruiting Boston Massachusetts 02115 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field